Our results suggest that TUBB3 may be a valuable prognostic marker for routine application in adenocarcinoma of the esophagus, especially to address the need for adjuvant treatment in individuals following neoadjuvant therapy and surgery. This evidence concerns the gene TUBB3 and esophageal adenocarcinoma.